monograph on 68Ga

Gallium (68Ga) chloride solution for radiolabelling
Reference: PA/PH/Exp. 14/T (08) 21 ANP
NOTE ON THE MONOGRAPH
The radionuclide gallium-68 is obtained by elution of a
68
Ge/68Ga generator using dilute hydrochloric acid. To
ensure a sufficiently low level of the parent radionuclide
germanium-68, the gallium-68 can either be adsorbed in the
form of [GaCl4]− on an anion exchange column followed by
elution from the column in the form of Ga3+ cations with water
or diluted hydrochloric acid, or be adsorbed in the form of
trivalent gallium on a cation exchange column followed by
elution with an acetone/hydrochloric acid mixture.
XXXX:2464
GALLIUM (68Ga) CHLORIDE SOLUTION
FOR RADIOLABELLING
Gallii (68Ga) chloridi solutio ad
radio-signandum
68
GaCl3
Mr 174.3
DEFINITION
Solution containing gallium-68 in the form of gallium chloride in
dilute hydrochloric acid. The preparation may contain acetone.
Content :
— gallium-68 : 90 per cent to 110 per cent of the declared
gallium-68 radioactivity at the date and time stated on the
label.
TESTS
pH : maximum 2, using a pH indicator strip R.
Bacterial endotoxins (2.6.14) : less than 175 IU/V, V being the
maximum volume to be used for the preparation of a single
patient dose, if intended for use in the manufacture of parenteral
preparations without a further appropriate procedure for the
removal of bacterial endotoxins. The solution may be released
for use before completion of the test.
Iron : maximum 10 μg/GBq.
Atomic absorption spectrometry (2.2.23, Method I).
Modifier solution : 14 g/L solution of magnesium nitrate R.
Test solution. Dilute the solution to be examined with a 1 per
cent V/V solution of nitric acid R to obtain a radioactivity
concentration of 2.5 MBq/mL.
Reference solutions. Prepare the reference solutions using iron
standard solution (20 ppm Fe) R, diluted as necessary with a
1 per cent V/V solution of nitric acid R(28).
Source: iron hollow-cathode lamp.
Wavelength : 248.3 nm.
Atomisation device : graphite furnace.
An example of the injection and instrument parameters for the
graphic furnace atomic absorption analysis is shown below.
Internal and external protective gas : argon R.
Injection : 20 μL of the corresponding solution + 1 μL of the
matrix modifier solution.
Injection temperature: 20 °C.
Furnace programme :
CHARACTERS
Appearance : clear, colourless solution.
Half-life and nature of radiation of gallium-68 : see general
chapter 5.7. Table of physical characteristics of radionuclides.
IDENTIFICATION
A. Test A for radionuclidic purity (see Tests) .
B. Determine the approximate half-life by no fewer than 3
measurements of the activity of a sample in the same
geometrical conditions within a suitable period of time (for
example, 15 min).
Result : 62 min to 74 min.
C. pH (see Tests).
D. To a volume of 20-100 μL(26) of the solution to be examined
add 1 mL of a 1.03 g/L solution of hydrochloric acid R.
Apply this solution to the top of a column containing strong
cation-exchange resin R(27), push 5 mL of air through the
column and collect the eluate. Determine the radioactivity
of the eluate (A1). Elute the column with 1 mL of a
1.03 g/L solution of of hydrochloric acid R. Determine
the radioactivity of the eluate (A2). Elute the column with
1 mL of a mixture of 2 volumes of hydrochloric acid R and
98 volumes of acetone R and push 5 mL of air through the
column. Determine the radioactivity of the eluate (A3) and
the residual activity on the column (A4).
Calculate the percentage of radioactivity in the A3 eluate
using the following expression :
Final temperature
(°C)
Ramp time
(s)
Hold time (s)
Internal
protection
gas flow
(mL/min)
Drying
110
1
30
250
Drying
130
15
30
250
Pyrolysis
1400
10
20
250
Atomisation
2100
0
5
0
Clean out
2450(29)
1
3
250
Zinc : maximum 10 μg/GBq.
Atomic absorption spectrometry (2.2.23, Method I).
Test solution. Dilute the solution to be examined with a 1 per
cent V/V solution of nitric acid R to obtain a radioactivity
concentration of 50 MBq/mL.
Reference solutions. Prepare the reference solutions using zinc
standard solution (10 ppm Zn) R, diluted as necessary with a
1 per cent V/V solution of nitric acid R(30).
Source: zinc hollow-cathode lamp.
Wavelength : 213.9 nm.
Atomisation device : air-acetylene flame.
RADIONUCLIDIC PURITY
The preparation may be released for use before completion of
test B.
Gallium-68 : minimum 99.9 per cent of the total radioactivity.
Result : the percentage of radioactivity in the A3 eluate is not A. Gamma-ray spectrometry.
less than 90 per cent.
Result : the gamma photons have energies of 0.511 MeV and
1.077 MeV ; depending on the measurement geometry, a sum
E. To 100 μL of silver nitrate solution R2 add 50 μL of the
peak of 1.022 MeV may be observed.
solution to be examined. A white precipitate is formed.
(26)
(27)
(28)
(29)
(30)
The volume is chosen so as to allow measurement of the radioactivity with sufficient accuracy.
Strata X-C 33 μm 10 mg/mL (Phenomenex) is suitable.
Dilutions of 50 μL, 100 μL, 150 μL and 200 μL of the standard solution in 100.0 mL were suitable when using a Perkin Elmer AAnalyst 800 instrument.
Verify instrument temperature limits.
Dilutions of 2.0 mL, 4.0 mL, 6.0 mL, 8.0 mL and 10.0 mL of the standard solution in 100.0 mL were suitable when using a Perkin Elmer AAnalyst 800 instrument.
508
© PHARMEUROPA Vol. 23, No. 3, July 2011
Members of the European Pharmacopoeia Commission: Austria, Belgium,
Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark,
Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia,
Lithuania, Luxembourg, Malta, Montenegro, Netherlands, Norway, Poland,
Portugal, Romania, Serbia, Slovak Republic, Slovenia, Spain, Sweden, Switzerland,
‘the former Yugoslav Republic of Macedonia’, Turkey, United Kingdom and
the European Union.
Observers to the European Pharmacopoeia Commission: Albania, Algeria,
Argentina, Armenia, Australia, Belarus, Brazil, Canada, China, Georgia, Israel,
Madagascar, Malaysia, Moldova, Morocco, Republic of Kazakhstan, Russian
Federation, Senegal, Syria, Tunisia, Ukraine, United States of America and
WHO (World Health Organization).
ADDRESSES OF THE NATIONAL PHARMACOPOEIA AUTHORITIES
parties to the European Pharmacopoeia Convention
Correspondence relating to the draft monographs submitted
for comment in the present issue are to be sent to the relevant authority.
AUSTRIA
Bundesministerium für
Gesundheit Familie und Jugend,
Arzneimittel und
Medizinprodukte
Radetzkystrasse 2
A 1030 WIEN
[email protected]
BELGIUM
Service public fédéral
Santé publique
Direction générale Médicaments
Place Victor Horta 40
BP 10
B 1060 BRUXELLES
[email protected]
BOSNIA AND
HERZEGOVINA
Institute for Quality Control
of Medicines
Titova 9
BA 71000 SARAJEVO
[email protected]
BULGARIA
Bulgarian Pharmacopoeia
Commission
Bulgarian Drug Agency
Damyan Gruev Str. 8
BG SOFIA 1303
[email protected]
CROATIA
Agency for medicinal products
and medical devices
Ksaverska cesta 4
HR 10000 ZAGREB
[email protected]
CYPRUS
How to contact us
Information and orders
Dr Louis Panayi
Department of Pharmaceutical
Services, Ministry of Health
CY 1475 LEFKOSIA
[email protected]
Internet: www.edqm.eu
European Directorate for the Quality of Medicines & HealthCare (EDQM)
Council of Europe - 7 allée Kastner
CS 30026, F-67081 STRASBOURG, FRANCE
Tel: +33 (0)3 88 41 30 30
Fax: +33 (0)3 88 41 27 71
Correspondence ....................................................................................................... Via the online Helpdesk (www.edqm.eu/hd)
How to place an order
Publications ...................................................................................................................................................https://www.edqm.eu/store
Reference standards ...................................................................................www.edqm.eu/site/EDQM_Reference_standards-649.html
Reference standards online order form...............................................................www.edqm/eu/site/CRS-order-form-697.html
Further information, including answers to the most frequently asked questions regarding ordering, is available via the Helpdesk.
Submission of scientific articles ................................................................................................................ [email protected]
All reference standards required for application of the monographs are available from the EDQM.
A catalogue of reference standards can be consulted on the EDQM website and printed directly. The list of newly released
reference standards (new reference standards and new batches) is available on the website http://crs.edqm.eu under the link
‘new’.
Printed on acid-free paper by Bialec, Nancy, France
CZECH REPUBLIC
Czech Pharmacopoeia
Commission
State Institute for Drug Control
Srobárova 48
CZ 100 41 PRAGUE 10
[email protected]
DENMARK
Danish Medicines Agency
Axel Heides Gade 1
DK 2300 KØBENHAVN S
[email protected]
ESTONIA
State Agency of Medicines
1 Nooruse Street
EE 50411 TARTU
[email protected]
FINLAND
Lääkelaitos Finnish
Medicines Agency
P.O. Box 55
FIN 00301 HELSINKI
[email protected]
FRANCE
Agence française de Sécurité
Sanitaire des Produits de Santé
Direction des Laboratoires et
des Contrôles
Unité Pharmacopée
143-147, bld. Anatole France
F 93285 SAINT-DENIS CEDEX
pharmacopeefrancaise@
afssaps.sante.fr
GERMANY
Geschäftsstelle der Deutschen
Arzneibuch-Kommission
Bundesinstitut für Arzneimittel
und Medizinprodukte
Kurt-Georg-Kiesinger Allee 3
D 53175 BONN
[email protected]
GREECE
Pharmacopoeia Section
National Organisation for
Medicines
Mesogeion Avenue, 284
GR 15562 HOLARGOS ATTIKIS
[email protected]
HUNGARY
National Institute of Pharmacy
Pharmacopoeia Section
Zrinyi u.3.
P.O. Box 450
H 1051 BUDAPEST
[email protected]
ICELAND
Head of the Pharmaceutical
Division,
Icelandic Medicines Control
Agency
Vinlandsleid 14
IS 113 REYKJAVIK
gunnar.thor.gunnarson@
lyfjastofnun.is
LITHUANIA
SLOVAK REPUBLIC
LUXEMBOURG
SLOVENIA
Lithuanian Pharmacopoeia
Commission
State Medicines Control Agency
Zirmuni St 139A
LT 09120 VILNIUS
[email protected]
Ministère de la Santé
Division de la Pharmacie et
des Médicaments
Villa Louvigny, Allée Marconi
L 2120 LUXEMBOURG
jacqueline.genoux-hames@
ms.etat.lu
MALTA
Malta Medicines Authority
203, Rue D’Argens,
GZR 1368
MT MALTA
[email protected]
NETHERLANDS
Secretariat of the Dutch
Pharmacopoeia Authority
Lab. for Quality Control of
Medicines
P.O.Box 1
NL 3720 BA BILTHOVEN
[email protected]
NORWAY
Norwegian Pharmacopoeia
Authority
Statens legemiddelverk
Sven Oftedals vei, 8
N 0950 OSLO
[email protected]
POLAND
Office for Registration of
Medical Products, Medical
Devices and Biocidal Products
Pharmacopoeia Unit
Ul. Zabkowska 41
PL 03-736 WARSZAWA
[email protected]
IRELAND
Irish Medicines Board
Earlsfort Centre
Earlsfort Terrace
IRL DUBLIN 2
[email protected]
ITALY
Segreteria Tecnica della
Farmacopea Ufficiale Italiana
Istituto Superiore di Sanità
Viale Regina Elena, 299
I 00161 ROMA
[email protected]
LATVIA
Latvia State Agency of
Medicines
Jersikas iela, 15
LV 1003 RIGA
[email protected]
PORTUGAL
Secrétariat de la Pharmacopée
Portugaise, Faculdade de
Farmacia
Rua Anibal Cunha
P 4050 PORTO
[email protected]
ROMANIA
National Medicines Agency
48, av. Sanatescu Str.
RO 71324 BUCHAREST
[email protected]
SERBIA
Medicines and Medical Devices
Agency of Serbia
458 Vojvode Stepe street
11152 BELGRADE
[email protected]
Statny ustav pre kontrolu lieciv
Slovenska liekopisna komisia
Kvetná 11
SK 825 08 BRATISLAVA
[email protected]
Javna agencija Republike
Slovenije za zdravila in
medicinske pripomocke
Ptujska ulica 21
SI 1000 LJUBLJANA
[email protected]
SPAIN
Real Farmacopea Espanola
Agencia Espanola de
Medicamentos y Productos
Sanitarios
Division de Quimica
y Tecnologia Farmaceutica
C/ Campezo 1
E 28022 MADRID
[email protected]
SWEDEN
Swedish Pharmacopoeia
Commission
Medical Products Agency
P.O. Box 26
S 751 03 UPPSALA
[email protected]
SWITZERLAND
Swissmedic, Swiss Agency for
Therapeutic Products,
Division Pharmacopoeia
Hallerstrasse 7
P. O. Box
CH 3000 BERN 9
[email protected]
“THE FORMER YUGOSLAV
REPUBLIC OF MACEDONIA”
Ministry of Health
Pharmaceutical Department
Divizija b.b., 50
MK 91000 SKOPJE
[email protected]
TURKEY
Ministry of Health
General Directorate of
Pharmaceuticals and Pharmacy
Sogutozu Mah 2176 Sok n°5
TR 06520 ANKARA CANKAYA
[email protected]
UNITED KINGDOM
British Pharmacopoeia
Commission
5th Floor
151 Buckingham Palace Road
LONDON
GB SW1W 9SZ
[email protected]